Symmetrical diamidates as a class of phosphate prodrugs to deliver the 5'-monophosphate form of anticancer nucleoside analogues

Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Ferrari, Valentina ORCID: https://orcid.org/0000-0003-1895-8906, Serpi, Michaela ORCID: https://orcid.org/0000-0002-6162-7910, Gonczy, Blanka, Balzarini, Jan and McGuigan, Christopher 2018. Symmetrical diamidates as a class of phosphate prodrugs to deliver the 5'-monophosphate form of anticancer nucleoside analogues. ChemMedChem 13 (21) , pp. 2305-2316. 10.1002/cmdc.201800504

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

We herein report on the application of phosphorodiamidate technology to both pyrimidine and purine nucleosides with anticancer activity. Sixteen symmetrical phosphorodiamidates esterified with natural amino acids such as L‐alanine and glycine were synthesized. All the compounds were evaluated for their cytotoxic activity in a wide panel of solid and leukemic tumour cell lines. In addition, a carboxypeptidase Y assay was performed on a representative phosphorodiamidate in order to reveal the putative bioactivation pathway for the reported phosphorodiamidate‐type prodrugs.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Publisher:	Wiley-VCH Verlag
ISSN:	1860-7179
Date of First Compliant Deposit:	19 September 2018
Date of Acceptance:	11 August 2018
Last Modified:	21 Feb 2024 16:48
URI:	https://orca.cardiff.ac.uk/id/eprint/115110

Citation Data

Cited 6 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item